NIBD/EBITDA before special items was 2.5x at the end of Q3 2025. The leverage ratio is within the target range of 2.0-3.0x and the share buyback program is ongoing. Embla Medical bought back 525,733 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback